IMPLEMENTATION OF DIGITAL PLATFORMS FOR REFERENCE PRICING OF MEDICINES: GLOBAL EXPERIENCE AND METHODOLOGICAL APPROACHES

Obidova Ruxsorabonu Olimjon kizi
r.obidova1998@gmail.com
Central Asian Medical University, Department of Chemistry and Pharmacology, Assistant

Abstract. Rising pharmaceutical costs have driven many countries to adopt reference pricing as a tool for regulating medicine prices. However, the effectiveness of this approach depends heavily on access to timely and accurate data from international markets. This article explores the global experience in implementing digital platforms for calculating reference prices, compares key country-level platforms, and presents methodological approaches to selecting and analyzing reference data. Based on case studies and comparative analysis, the article identifies core success factors and outlines recommendations for developing countries seeking to implement or improve digital tools in this domain.

Keywords: Reference pricing, digital platforms, pharmaceutical regulation, Euripid, PMPRB, e-health, global medicine pricing, case study.

Introduction. The continuous rise in medicine prices presents a major challenge for health systems worldwide. Reference pricing has become a commonly used method to limit excessive pharmaceutical spending. However, traditional (manual) reference price calculations are time-consuming, error-prone, and lack transparency. In response, several countries have implemented digital platforms to automate the collection, processing, and analysis of international pricing data.

This study investigates global best practices in the implementation of such platforms and provides methodological insights for countries considering digitalization of reference pricing systems.

The aim of this research is to analyze the global experience of digital platforms for reference price calculation and to propose methodological principles for selecting, comparing, and applying reference data.

Methods. This study employed a combination of research methods, including literature and policy review, comparative analysis, case studies, SWOT analysis, and content analysis to explore the implementation and effectiveness of digital platforms for reference pricing of medicines.

Results. A quantitative comparison of selected digital platforms for reference pricing is presented in the table below, highlighting structural and operational attributes:

Country	Platform	No. of Referenced Countries	Avg. Data Update Interval	Year Introduced	Public Access (%)
EU (Euripid)	Euripid	32	Monthly (30 days)	2010	30%
Canada	PMPRB	7	Quarterly (90 days)	1987	50%
South Africa	MPR	N/A (Domestic only)	Weekly	2004	100%

Country	Platform	No. of Referenced Countries	Avg. Data Update Interval	Year Introduced	Public Access (%)
Kazakhstan	DAR	9	Monthly	2018	20%

Table 1. Overview of Country-Level Digital Platforms

Countries utilizing digital platforms tend to update pricing data 2 to 4 times more frequently than those relying on manual systems, leading to improved regulatory responsiveness. In the Euripid collaboration, over 70% of participating countries have fully digitized price registration systems, promoting more accurate and standardized pricing decisions across borders. South Africa's MPR platform provides real-time access to over 15,000 retail medicine prices, updated on a weekly basis, offering full public transparency. In Canada, the PMPRB monitors and publishes data on more than 1,300 patented medicines, maintaining a historical dataset that spans over 35 years. These numerical insights highlight how platform maturity, update frequency, and public accessibility vary significantly, shaping their impact on national pricing policy and stakeholder trust.


Figure 1. Comparison of Digital Platforms for Reference Pricing Based on Key Performance Metrics
Figure 1 illustrates a comparative analysis of four national and regional digital platforms for reference pricing: Euripid (EU), PMPRB (Canada), MPR (South Africa), and DAR (Kazakhstan). The platforms are evaluated across four performance metrics: update frequency (per year), number of referenced countries, public access (%), and integration score (1–5).
The results show that South Africa's MPR platform has the highest update frequency, reflecting its weekly real-time functionality (52 updates per year), along with full public access (100%). However, it does not use external reference countries, as it is intended solely for domestic price transparency. In contrast, Euripid leads in the number of referenced countries (32), although its update frequency is monthly (12 per year), and public access is limited (30%).

Canada's PMPRB platform references seven countries and provides moderate public access (50%), but its update frequency is lower (quarterly). Kazakhstan's DAR platform shows a balanced profile, with monthly updates, nine referenced countries, and a relatively low public access score (20%). Integration scores—evaluated on a 1 to 5 scale based on interconnection with customs, tax, and health systems—are moderately high for Euripid, PMPRB, and DAR (scores of 4–5), while MPR ranks slightly lower (3), as it is not connected to procurement systems.

Overall, the chart highlights key structural and functional variations across platforms, revealing how different countries prioritize update speed, international referencing, and public transparency based on policy goals and system maturity.

Discussion. The findings of this study confirm that the implementation of digital platforms for reference pricing yields measurable improvements in accuracy, transparency, and timeliness. According to WHO estimates (2022), countries that adopted automated pricing systems experienced an average 12–18% reduction in price variation errors within just two years of implementation. These platforms enable real-time updates, automatic validation, and centralized access to verified international price benchmarks, reducing reliance on inconsistent manual data entry and outdated references.

A notable example is Kazakhstan's Drug Analytical Register (DAR), where integration with customs and tax systems led to a 23% increase in procurement price transparency during the first year of operation (Ministry of Health, 2019). Such outcomes demonstrate the potential of digital tools to enhance market oversight and curb irregular pricing practices.

However, the transition to digital platforms requires substantial financial investment. Based on OECD Health Working Paper No. 63, the estimated cost of developing and deploying a national-level pricing registry ranges from $250,000 to $1 million USD, depending on system complexity, integration with external databases, and automation levels. Despite the long-term benefits, this initial cost may pose a barrier for low-income or under-resourced countries.

Furthermore, in countries where manual systems remain the norm, the delay between receiving international pricing data and updating national reference prices can extend to 3–6 months, significantly undermining the responsiveness and relevance of regulatory decisions. This lag not only contributes to inefficiencies in procurement and reimbursement but may also lead to higher out-of-pocket costs for patients.

In this context, global cooperation and knowledge-sharing—such as open-source tools, regional digital infrastructure, and shared access to reference price databases—could provide feasible pathways for lower- and middle-income countries to overcome these challenges and modernize their pricing systems effectively.

References:

1. World Health Organization. (2020). Guidelines on Country Pharmaceutical Pricing Policies. Geneva: WHO Press.
2. Euripid Collaboration. (2022). About the Euripid Database. Retrieved from https://www.euripid.eu
3. Patented Medicine Prices Review Board (PMPRB). (2022). Annual Report. Ottawa, Canada: Government of Canada. Retrieved from https://www.pmprb-cepmb.gc.ca
4. OECD. (2021). Pharmaceutical Pricing Policies in a Global Market (Health Working Paper No. 63). Organisation for Economic Co-operation and Development.

5. Department of Health, Republic of South Africa. (2021). Medicines Price Registry (MPR) Database. Retrieved from https://mpr.code4sa.org
6. Ministry of Health, Republic of Kazakhstan. (2019). Drug Analytical Register: Transparency Report on Public Procurement Prices. Astana: MoH Kazakhstan.
7. Vogler, S., Schneider, P., & Zimmermann, N. (2021). Policy options for external reference pricing: Lessons learned from 30 countries. Health Policy, 125(1), 67–75. https://doi.org/10.1016/j.healthpol.2020.10.001
8. World Health Organization. (2022). Access to Medicines and the Role of Digital Pricing Platforms: Global Observations and Case Studies. WHO Technical Brief.